Brigatinib CAS 1197953-54-0 Purity >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Brigatinib (AP-26113) (CAS: 1197953-54-0) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Brigatinib, Please contact: alvin@ruifuchem.com
| Chemical Name | Brigatinib |
| Synonyms | AP26113; AP-26113; 5-Chloro-N4-[2-(Dimethylphosphinyl)phenyl]-N2-[2-Methoxy-4-[4-(4-Methyl-1-Piperazinyl)-1-Piperidinyl]phenyl]-2,4-Pyrimidinediamine |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 1197953-54-0 |
| Molecular Formula | C29H39ClN7O2P |
| Molecular Weight | 584.09 g/mol |
| Melting Point | >203℃(dec.) |
| Density | 1.31±0.10 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | White to Off-White Powder | Complies |
| Purity / Analysis Method | >99.0% (HPLC) | 99.26% |
| Max. Single Impurity | <1.00% | 0.25% |
| Loss on Drying | <1.00% | 0.27% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Brigatinib (AP-26113) (CAS: 1197953-54-0) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib is a medicine used to treat cancer that suppresses epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Brigatinib is a selective agonist against variations of EGFR as opposed to the wild mutant forms. The drug also illustrates selectivity against the ALK-EML4 fusion gene, which is a fundamental aspect of the modification of susceptible lung parenchyma. Brigatinib is prescribed for patients with specific abnormal genes and when the non-small cell lung cancer (NSCLC) is non-responsive to management with other medications. Brigatinib is classified as a kinase inhibitor, whose mechanism of action entails suppressing the action of abnormal proteins that enhance the multiplication of cancer cells.
Brigatinib (CAS: 1197953-54-0) is prescribed for patients with specific forms of NSCLC that have spread to various sections of the body in people who have been on previous treatment with other cancer medications such as Crizotinib, and their condition has become worse or they indicate minimal signs of improvement. It is mainly under investigation for its treatmentefficacy on non-small cell lung cancer (NSCLC) where ALK is activated and EGFP mutations frequently occur.
Brigatinib (AP-26113) (CAS: 1197953-54-0) is a new-generation inhibitor of tyrosine kinase, showing significant efficacy in ALK+ metastatic NSCLC. On August 30, 2016, the United States FDA granted bugtinib as breakthrough therapy and rare drug for ALK+NSCLC in patients who have developed or cannot tolerate Crizotinib, the first-generation ALK+NSCLC treatment. Give priority to the listing application review and allow the application data to be submitted on a rolling basis. The FDA approved Bugtinib on April 28, 2017, under the trade name Alunbrigtm.
